Roche licenses Simcere Zaiming's preclinical trispecific T cell engager SIM0660 for $75M upfront, up to $1.53B in biobucks, its second China biotech deal this month.
For the second time in as many weeks, Roche’s business development team has lined up a deal with a Chinese biopharma.
The Swiss drug giant …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment…
Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after…
Roche licenses Hanmi Pharm's non-incretin obesity drug HM17321 in a deal worth up to $2.3B, including $190M upfront.
With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a less-trodden…
